PURE Bioscience, Inc.
PURE
$0.0688
$0.013825.09%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.80M | 1.96M | 2.09M | 2.06M | 2.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.80M | 1.96M | 2.09M | 2.06M | 2.13M |
| Cost of Revenue | 762.00K | 811.00K | 893.00K | 921.00K | 972.00K |
| Gross Profit | 1.04M | 1.15M | 1.20M | 1.14M | 1.16M |
| SG&A Expenses | 3.79M | 3.98M | 4.10M | 4.10M | 4.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.84M | 5.09M | 5.29M | 5.32M | 5.48M |
| Operating Income | -3.05M | -3.13M | -3.20M | -3.26M | -3.35M |
| Income Before Tax | -3.30M | -3.35M | -3.63M | -3.65M | -3.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.30 | -3.35 | -3.63 | -3.65 | -3.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.30M | -3.35M | -3.63M | -3.65M | -3.70M |
| EBIT | -3.05M | -3.13M | -3.20M | -3.26M | -3.35M |
| EBITDA | -2.90M | -2.98M | -3.08M | -3.14M | -3.23M |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 447.43M | 447.43M | 447.12M | 446.62M | 446.12M |
| Average Diluted Shares Outstanding | 447.43M | 447.43M | 447.12M | 446.62M | 446.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
